Cardiol Therapeutics Inc. (NASDAQ:CRDL - Free Report) - Leede Financial reduced their FY2027 earnings estimates for Cardiol Therapeutics in a research note issued on Tuesday, November 19th. Leede Financial analyst D. Loe now expects that the company will earn $0.16 per share for the year, down from their previous forecast of $0.18. The consensus estimate for Cardiol Therapeutics' current full-year earnings is ($0.36) per share. Leede Financial also issued estimates for Cardiol Therapeutics' FY2028 earnings at $0.74 EPS.
Separately, HC Wainwright reissued a "buy" rating and issued a $9.00 target price on shares of Cardiol Therapeutics in a report on Thursday, October 24th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $8.75.
Get Our Latest Report on CRDL
CRDL opened at $1.65 on Wednesday. Cardiol Therapeutics has a twelve month low of $0.79 and a twelve month high of $3.12. The company has a 50-day simple moving average of $1.99 and a 200 day simple moving average of $2.09. The company has a quick ratio of 2.49, a current ratio of 2.49 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $134.64 million, a price-to-earnings ratio of -4.23 and a beta of 0.91.
Several institutional investors and hedge funds have recently made changes to their positions in CRDL. AdvisorShares Investments LLC increased its stake in shares of Cardiol Therapeutics by 12.7% in the second quarter. AdvisorShares Investments LLC now owns 1,466,972 shares of the company's stock valued at $2,934,000 after buying an additional 164,994 shares during the period. Foundations Investment Advisors LLC increased its stake in shares of Cardiol Therapeutics by 237.4% in the third quarter. Foundations Investment Advisors LLC now owns 161,950 shares of the company's stock valued at $321,000 after buying an additional 113,950 shares during the period. Lion Street Advisors LLC increased its stake in shares of Cardiol Therapeutics by 31.4% in the second quarter. Lion Street Advisors LLC now owns 253,281 shares of the company's stock valued at $505,000 after buying an additional 60,581 shares during the period. Baader Bank Aktiengesellschaft acquired a new position in shares of Cardiol Therapeutics in the second quarter valued at approximately $59,000. Finally, Jane Street Group LLC acquired a new stake in Cardiol Therapeutics during the 3rd quarter valued at approximately $29,000. Institutional investors and hedge funds own 12.49% of the company's stock.
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Cardiol Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardiol Therapeutics wasn't on the list.
While Cardiol Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.